- Home
- AMT vs VRTX Comparison
AMT vs VRTX Comparison
Compare AMT & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMT
- VRTX
- Stock Information
- Founded
- AMT 1995
- VRTX 1989
- Country
- AMT United States
- VRTX United States
- Employees
- AMT N/A
- VRTX N/A
- Industry
- AMT Real Estate Investment Trusts
- VRTX EDP Services
- Sector
- AMT Real Estate
- VRTX Technology
- Exchange
- AMT Nasdaq
- VRTX Nasdaq
- Market Cap
- AMT 107.6B
- VRTX 115.6B
- IPO Year
- AMT 1998
- VRTX 1991
- Fundamental
- Price
- AMT $214.33
- VRTX $400.20
- Analyst Decision
- AMT Strong Buy
- VRTX Buy
- Analyst Count
- AMT 17
- VRTX 24
- Target Price
- AMT $243.82
- VRTX $496.76
- AVG Volume (30 Days)
- AMT 2.3M
- VRTX 2.5M
- Earning Date
- AMT 07-29-2025
- VRTX 08-04-2025
- Dividend Yield
- AMT 3.09%
- VRTX N/A
- EPS Growth
- AMT N/A
- VRTX N/A
- EPS
- AMT 2.77
- VRTX 14.07
- Revenue
- AMT $10,259,600,000.00
- VRTX $11,418,800,000.00
- Revenue This Year
- AMT $3.35
- VRTX $10.40
- Revenue Next Year
- AMT $4.77
- VRTX $10.63
- P/E Ratio
- AMT $75.73
- VRTX $28.24
- Revenue Growth
- AMT 2.24
- VRTX 10.46
- 52 Week Low
- AMT $172.51
- VRTX $362.50
- 52 Week High
- AMT $243.56
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- AMT 49.62
- VRTX 43.02
- Support Level
- AMT $202.66
- VRTX $388.93
- Resistance Level
- AMT $211.14
- VRTX $400.94
- Average True Range (ATR)
- AMT 3.50
- VRTX 12.48
- MACD
- AMT 0.65
- VRTX 1.47
- Stochastic Oscillator
- AMT 88.42
- VRTX 72.97
About AMT American Tower Corporation (REIT)
American Tower owns and operates more than 220,000 cell towers throughout the US, Asia, Latin America, Europe, and Africa. It also owns and/or operates 28 data centers in 10 US markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the US, which accounted for almost half of the company's total revenue in 2023. Outside the US, American Tower operates over 75,000 towers in India, almost 50,000 towers in Latin America (dominated by Brazil), 30,000 towers in Europe, and nearly 25,000 towers in Africa. American Tower operates as a REIT.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.